Literature DB >> 23594457

The -308G/A polymorphism of the tumor necrosis factor-alpha gene is associated with the risk of upper aerodigestive tract cancer: a meta-analysis.

Jiayi Wang1, Xin Jin, Hui Wang, Jiantang Yang, Lili Wang, Lei Lei, Xiaoxu Li, Yu Zhou, Xin Zeng, Lu Jiang, Ga Liao, Hongxia Dan, Qianming Chen.   

Abstract

Tumor necrosis factor-alpha (TNF-α) has been proposed to contribute to the development of upper aerodigestive tract (UADT) cancer that is characterized by poor prognosis. The G-to-A nucleotide change at -308 of the TNF-α gene (-308G/A polymorphism) can increase the expression level of TNF-α and thus may affect the genetic susceptibility of UADT cancer. The association between the -308G/A polymorphism and UADT cancer has been widely studied, but the results published are quite controversial. To obtain a more precise conclusion, we performed a meta-analysis including 1,751 patients and 3,345 controls. The results indicated that the AA genotype of the -308G/A polymorphism had a 54%-increased risk of UADT cancer, compared with the G carriers (GG and GA genotypes) [odds ratio (OR) = 1.54, 95% confidence interval (CI): 1.07-2.21]. After stratified by ethnicity, the AA genotype was associated with increased risk of UADT cancers in South Asians (OR = 33.18 and 95% CI: 1.92-573.62 for AA vs. GA+GG) but not in Caucasians or East Asians. After stratified by tumor site, the -308G/A polymorphism was associated with increased risks of oropharynx cancer (OR = 2.68 and 95% CI: 1.34-5.35 for AA vs. GA+GG) but not associated with esophagus or larynx cancer. After stratified by histological type, the -308G/A polymorphism was associated with increased risks of squamous cell carcinoma (OR = 1.81 and 95% CI: 1.15-2.84 for AA vs. GA+GG) but not associated with adenocarcinoma. Our results indicate that the -308G/A polymorphism might contribute to an increased risk of UADT cancer susceptibility.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23594457     DOI: 10.1620/tjem.229.245

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  8 in total

1.  Association of XRCC1 genetic polymorphism (Arg399Gln) with laryngeal cancer: a meta-analysis based on 4,031 subjects.

Authors:  W Chen; Z Y Wang; F L Xu; K M Wu; Y Zhang; L Xu; Q P Wang
Journal:  Tumour Biol       Date:  2013-11-06

2.  Haplotype analysis of the XRCC1 gene and laryngeal cancer.

Authors:  Wei Chen; Li Xu; Zhi-Yi Wang; Li-Jun Xue; Feng-Lei Xue; Man-Jie Jiang; Qiu-Ping Wang; Hong-Liang Zheng
Journal:  Genet Test Mol Biomarkers       Date:  2014-06-23

3.  Association of C722T polymorphism in XRCC3 gene with larynx cancer: a meta-analysis.

Authors:  Dong Li; Hui-Hua You; Yuan-Jing Jia; Jian-Dong Guo; Huan-Le Du
Journal:  Tumour Biol       Date:  2014-02-13

4.  Haplotype analysis of RECQL5 gene and laryngeal cancer.

Authors:  Ying Qi; Xu Zhou
Journal:  Tumour Biol       Date:  2013-11-09

5.  The association between hypoxia-inducible factor-1 α gene C1772T polymorphism and cancer risk: a meta-analysis of 37 case-control studies.

Authors:  Pengfei He; Qi Han; Jiajia Liu; Dongjuan Liu; Xin Zhao; Ting Hu; Lu Jiang; Hongxia Dan; Xin Zeng; Jing Li; Jiayi Wang; Qianming Chen
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

6.  Tumor necrosis factor-α (TNF-α)-308G/A promoter polymorphism in colorectal cancer in ethnic Kashmiri population - A case control study in a detailed perspective.

Authors:  Mujeeb Zafar Banday; Henah Mehraj Balkhi; Zeenat Hamid; Aga Syed Sameer; Nissar A Chowdri; Ehtishamul Haq
Journal:  Meta Gene       Date:  2016-06-03

7.  Genetic association between TNF-α promoter polymorphism and susceptibility to squamous cell carcinoma, basal cell carcinoma, and melanoma: A meta-analysis.

Authors:  Ning Liu; Guang-Jing Liu; Juan Liu
Journal:  Oncotarget       Date:  2017-04-18

8.  Determination of SIRT1 rs12778366, FGFR2 rs2981582, STAT3 rs744166, and RAGE rs1800625 Single Gene Polymorphisms in Patients with Laryngeal Squamous Cell Carcinoma.

Authors:  Virgilijus Uloza; Toma Tamauskaite; Alvita Vilkeviciute; Agne Pasvenskaite; Vykintas Liutkevicius; Rasa Liutkeviciene
Journal:  Dis Markers       Date:  2019-11-12       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.